Compare GSK plc (GSK) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Huntington Bancshares Incorporated — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Huntington Bancshares Incorporated trades at $18.58 (market cap $36.74B). The key difference: GSK plc is far larger — about 2.8× Huntington Bancshares Incorporated's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | HBAN | |
|---|---|---|
Market Cap | $101.34B | $36.74B |
Sector | Health | Financials |
52-Week High | $61.18 | $19.27 |
52-Week Low | $36.20 | $15.02 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 3.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Huntington Bancshares (HBAN) trades at $18.48, up 3.53% today, with a bullish technical outlook and strong analyst consensus. Recent Q1 2026 earnings beat expectations, and the company shows revenue growth to $8.13B in 2025. Key financials include a P/E of 13.94 and net income margin of 25.13%. Positive news highlights expansion in Texas and a recent banking tech award, supporting investor optimism.
HBAN presents a favorable investment case with upside to the $20.25 consensus price target, driven by earnings growth and strategic acquisitions. Risks include integration challenges from M&A and competitive pressures in regional banking. The stock's valuation remains reasonable, but investors should monitor execution on synergy targets and interest rate impacts on net interest margin.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
